Shares of Telik (TELK +57.2%) are soaring on heavy volume following a brief halt after the FDA...

|By:, SA News Editor

Shares of Telik (TELK +57.2%) are soaring on heavy volume following a brief halt after the FDA grants orphan drug status for Telintra, a treatment for myelodysplastic syndrome.